Prostate Cancer Research Today is a free monthly online journal that collates and summarizes the latest research about Prostate Cancer, including details on symptoms, genetics, screening, treatment, information.

Volume 4 (2007), Issue 2 (February)

1. Effect of nitric-oxide synthesis on tumour blood volume and vascular activity: a phase I study.
   Lancet Oncol, 8(2): 111-8. [Abstract] [Full-text]
2. Overcoming the radioresistance of prostate cancer cells with a novel Bcl-2 inhibitor.
   Oncogene, 26(5): 652-61. [Abstract] [Full-text]
3. Neurotensin stimulates mitogenesis of prostate cancer cells through a novel c-Src/Stat5b pathway.
   Oncogene, 26(5): 745-56. [Abstract] [Full-text]
4. Unusual and underappreciated: small cell carcinoma of the prostate.
   Semin Oncol, 34(1): 22-9. [Abstract] [Full-text]
5. Highly tumorigenic human androgen receptor-positive prostate cancer cells overexpress angiogenin.
   Cancer Sci, 98(3): 350-6. [Abstract] [Full-text]
6. Novel expressed sequences identified in a model of androgen independent prostate cancer.
   BMC Genomics, 8: 32. [Abstract] [Full-text]
7. Integrating transcription factor binding site information with gene expression datasets.
   Bioinformatics, 23(3): 298-305. [Abstract] [Full-text]
8. A prospective cohort study of red wine consumption and risk of prostate cancer.
   Int J Cancer, 120(7): 1529-35. [Abstract] [Full-text]
9. Detection of tumor-specific DNA in blood and bone marrow plasma from patients with prostate cancer.
   Int J Cancer, 120(7): 1465-71. [Abstract] [Full-text]
10. Differential effects of naturally occurring and synthetic organoselenium compounds on biomarkers in androgen responsive and androgen independent human prostate carcinoma cells.
    Int J Cancer, 120(7): 1410-7. [Abstract] [Full-text]
11. Free PSA isoforms and intact and cleaved forms of urokinase plasminogen activator receptor in serum improve selection of patients for prostate cancer biopsy.
    Int J Cancer, 120(7): 1499-504. [Abstract] [Full-text]
12. Impaired dihydrotestosterone catabolism in human prostate cancer: critical role of AKR1C2 as a pre-receptor regulator of androgen receptor signaling.
    Cancer Res, 67(3): 1361-9. [Abstract] [Full-text]
13. In vivo effects of vaccination with six-transmembrane epithelial antigen of the prostate: a candidate antigen for treating prostate cancer.
    Cancer Res, 67(3): 1344-51. [Abstract] [Full-text]
14. Inhibition of fatty acid synthase induces endoplasmic reticulum stress in tumor cells.
    Cancer Res, 67(3): 1262-9. [Abstract] [Full-text]
15. The type III transforming growth factor-beta receptor as a novel tumor suppressor gene in prostate cancer.
    Cancer Res, 67(3): 1090-8. [Abstract] [Full-text]
16. The androgen receptor negatively regulates the expression of c-Met: implications for a novel mechanism of prostate cancer progression.
    Cancer Res, 67(3): 967-75. [Abstract] [Full-text]
17. Demethylation-linked activation of urokinase plasminogen activator is involved in progression of prostate cancer.
    Cancer Res, 67(3): 930-9. [Abstract] [Full-text]
18. The dietary charred meat carcinogen 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine acts as both a tumor initiator and promoter in the rat ventral prostate.
    Cancer Res, 67(3): 1378-84. [Abstract] [Full-text]
19. Signaling mechanisms of melatonin in antiproliferation of hormone-refractory 22Rv1 human prostate cancer cells: implications for prostate cancer chemoprevention.
    J Pineal Res, 42(2): 191-202. [Abstract] [Full-text]
20. A pilot study of the vulnerable elders survey-13 compared with the comprehensive geriatric assessment for identifying disability in older patients with prostate cancer who receive androgen ablation.
    Cancer, 109(4): 802-10. [Abstract] [Full-text]
21. Prospective study of adiposity and weight change in relation to prostate cancer incidence and mortality.
    Cancer, 109(4): 675-84. [Abstract] [Full-text]
22. hPEBP4 resists TRAIL-induced apoptosis of human prostate cancer cells by activating Akt and deactivating ERK1/2 pathways.
    J Biol Chem, 282(7): 4943-50. [Abstract] [Full-text]
23. Differential effects of endoplasmic reticulum stress-induced autophagy on cell survival.
    J Biol Chem, 282(7): 4702-10. [Abstract] [Full-text]
24. Site-specific acetylation of p53 directs selective transcription complex assembly.
    J Biol Chem, 282(7): 4765-71. [Abstract] [Full-text]
25. Comparison of localization performance with implanted fiducial markers and cone-beam computed tomography for on-line image-guided radiotherapy of the prostate.
    Int J Radiat Oncol Biol Phys, 67(3): 942-53. [Abstract] [Full-text]
26. Long-term follow-up of 111In-capromab pendetide (ProstaScint) scan as pretreatment assessment in patients who undergo salvage radiotherapy for rising prostate-specific antigen after radical prostatectomy for prostate cancer.
    Int J Radiat Oncol Biol Phys, 67(3): 834-40. [Abstract] [Full-text]
27. Brachytherapy versus prostatectomy in localized prostate cancer: results of a French multicenter prospective medico-economic study.
    Int J Radiat Oncol Biol Phys, 67(3): 812-22. [Abstract] [Full-text]
28. X-ray-assisted positioning of patients treated by conformal arc radiotherapy for prostate cancer: comparison of setup accuracy using implanted markers versus bony structures.
    Int J Radiat Oncol Biol Phys, 67(3): 823-7. [Abstract] [Full-text]
29. Reducing metal artifacts in cone-beam CT images by preprocessing projection data.
    Int J Radiat Oncol Biol Phys, 67(3): 924-32. [Abstract] [Full-text]
30. The predictive value of 2-year posttreatment biopsy after prostate cancer radiotherapy for eventual biochemical outcome.
    Int J Radiat Oncol Biol Phys, 67(3): 828-33. [Abstract] [Full-text]
31. Reduced late rectal mucosal changes after prostate three-dimensional conformal radiotherapy with endorectal balloon as observed in repeated endoscopy.
    Int J Radiat Oncol Biol Phys, 67(3): 799-811. [Abstract] [Full-text]
32. Lack of demonstrable autocrine hedgehog signaling in human prostate cancer cell lines.
    J Urol, 177(3): 1179-85. [Abstract] [Full-text]
33. 13-year outcomes following treatment for clinically localized prostate cancer in a population based cohort.
    J Urol, 177(3): 932-6. [Abstract] [Full-text]
34. Comparison of length of hospital stay between radical retropubic prostatectomy and robotic assisted laparoscopic prostatectomy.
    J Urol, 177(3): 929-31. [Abstract] [Full-text]
35. The effect of brachytherapy, external beam irradiation and hormonal therapy on prostate volume.
    J Urol, 177(3): 925-8. [Abstract] [Full-text]
36. The effect of androgen deprivation therapy on periodontal disease in men with prostate cancer.
    J Urol, 177(3): 921-4. [Abstract] [Full-text]
37. Sentinel lymph node dissection for prostate cancer: experience with more than 1,000 patients.
    J Urol, 177(3): 916-20. [Abstract] [Full-text]
38. Long-term survival in men with high grade prostate cancer: a comparison between conservative treatment, radiation therapy and radical prostatectomy--a propensity scoring approach.
    J Urol, 177(3): 911-5. [Abstract] [Full-text]
39. Validation of a prediction model for low volume/low grade cancer: application in selecting patients for active surveillance.
    J Urol, 177(3): 907-10. [Abstract] [Full-text]
40. The relationship between serum prostate specific antigen level and tumor volume persists in the current era.
    J Urol, 177(3): 903-6. [Abstract] [Full-text]
41. Prostate specific antigen velocity threshold for predicting prostate cancer in young men.
    J Urol, 177(3): 899-902. [Abstract] [Full-text]
42. Association of testis derived transcript gene variants and prostate cancer risk.
    J Urol, 177(3): 894-8. [Abstract] [Full-text]
43. Bladder cancer incidence and risk factors in men with prostate cancer: results from Cancer of the Prostate Strategic Urologic Research Endeavor.
    J Urol, 177(3): 883-7; discussion 887-8. [Abstract] [Full-text]
44. Hedgehog signaling in the prostate.
    J Urol, 177(3): 832-8. [Abstract] [Full-text]
45. The expanding role of epigenetics in the development, diagnosis and treatment of prostate cancer and benign prostatic hyperplasia.
    J Urol, 177(3): 822-31. [Abstract] [Full-text]
46. Efficient transfection of tumors facilitated by long-term therapeutic ultrasound in combination with contrast agent: from in vitro to in vivo setting.
    Cancer Gene Ther, 14(3): 306-15. [Abstract] [Full-text]
47. The histone deacetylase inhibitors depsipeptide and MS-275, enhance TRAIL gene therapy of LNCaP prostate cancer cells without adverse effects in normal prostate epithelial cells.
    Cancer Gene Ther, 14(3): 327-34. [Abstract] [Full-text]
48. Two-step amplification of the human PPT sequence provides specific gene expression in an immunocompetent murine prostate cancer model.
    Cancer Gene Ther, 14(3): 233-40. [Abstract] [Full-text]
49. Histamine augments beta2-adrenoceptor-induced cyclic AMP accumulation in human prostate cancer cells DU-145 independently of known histamine receptors.
    Biochem Pharmacol, 73(6): 814-23. [Abstract] [Full-text]
50. 3rd PacRim Breast and Prostate Cancer Meeting. 31 October-4 November 2006, Fraser Island, Queensland, Australia.
    Expert Opin Investig Drugs, 16(3): 397-401. [Abstract] [Full-text]
51. Manipulation of the nerve growth factor network in prostate cancer.
    Expert Opin Investig Drugs, 16(3): 303-9. [Abstract] [Full-text]
52. Androgen receptor amplification is associated with increased cell proliferation in prostate cancer.
    Hum Pathol, 38(3): 474-8. [Abstract] [Full-text]
53. Rapid suppression of plasma testosterone levels and tumor growth in the dunning rat model treated with degarelix, a new gonadotropin-releasing hormone antagonist.
    J Pharmacol Exp Ther, 320(3): 1113-8. [Abstract] [Full-text]
54. Suppression of androgen receptor transactivation and prostate cancer cell growth by heterogeneous nuclear ribonucleoprotein A1 via interaction with androgen receptor coregulator ARA54.
    Endocrinology, 148(3): 1340-9. [Abstract] [Full-text]
55. Efficacy and safety of single-agent pertuzumab (rhuMAb 2C4), a human epidermal growth factor receptor dimerization inhibitor, in castration-resistant prostate cancer after progression from taxane-based therapy.
    J Clin Oncol, 25(6): 675-81. [Abstract] [Full-text]
56. Double-blinded randomized study of high-dose calcitriol plus docetaxel compared with placebo plus docetaxel in androgen-independent prostate cancer: a report from the ASCENT Investigators.
    J Clin Oncol, 25(6): 669-74. [Abstract] [Full-text]
57. Prostate cancer susceptibility is mediated by interactions between exposure to ultraviolet radiation and polymorphisms in the 5' haplotype block of the vitamin D receptor gene.
    Cancer Lett, 247(2): 328-35. [Abstract] [Full-text]
58. The effect of positional realignment on dose delivery to the prostate and organs-at-risk for 3DCRT.
    Med Dosim, 32(1): 1-6. [Abstract] [Full-text]
59. EUS for locoregional staging of prostate cancer--a pilot study.
    Gastrointest Endosc, 65(3): 440-7. [Abstract] [Full-text]
60. Effects of freezing on membranes and proteins in LNCaP prostate tumor cells.
    Biochim Biophys Acta, 1768(3): 728-36. [Abstract] [Full-text]
61. Mechanisms involved in resveratrol-induced apoptosis and cell cycle arrest in prostate cancer-derived cell lines.
    J Androl, 28(2): 282-93. [Abstract] [Full-text]
62. Discovery of candidate tumor markers for prostate cancer via proteomic analysis of cell culture-conditioned medium.
    Clin Chem, 53(3): 429-37. [Abstract] [Full-text]

© 2004-2008 Prostate Cancer Research Today. All Rights Reserved.